Volitionrx limited announces closing of $16.5 million underwritten public offering of common stock

Henderson, nev. , june 5, 2023 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, announced today the closing of its previously announced underwritten public offering of its common stock generating gross proceeds to volition from the offering of approximately $16.5 million, before deducting underwriting commissions and other offering expenses payable by volition.
VNRX Ratings Summary
VNRX Quant Ranking